Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Income Statement
Shanghai Fosun Pharmaceutical (Group) Co Income Statement
Last quarter (Q3 2026), Shanghai Fosun Pharmaceutical (Group) Co's total revenue was $10.02B, an increase of 1.44% from the same quarter last year. In Q3, Shanghai Fosun Pharmaceutical (Group) Co's net income was $946.02M. See Shanghai Fosun Pharmaceutical (Group) Co’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 40.42B | $ 41.07B | $ 41.40B | $ 43.95B | $ 39.01B | |
| $ 20.16B | $ 19.70B | $ 19.68B | $ 20.78B | $ 18.78B | |
| $ 17.63B | $ 15.46B | $ 16.50B | $ 17.15B | $ 16.06B | |
| Depreciation and Amortization | $ 3.51B | $ 3.00B | $ 2.97B | $ 2.34B | $ 1.83B |
| $ 6.05B | $ 8.60B | $ 7.55B | $ 7.87B | $ 8.70B | |
| $ 2.54B | $ 4.25B | $ 3.31B | $ 8.30B | $ 6.31B | |
| $ 2.44B | $ -75.82M | $ -42.94M | $ -82.27M | $ -259.90M | |
| $ 4.98B | $ 4.17B | $ 3.26B | $ 4.57B | $ 6.05B | |
| $ 3.28B | $ 2.77B | $ 2.39B | $ 3.73B | $ 4.73B | |
| Per Share Metrics | |||||
| Basic EPS | $ 1.24 | $ 1.04 | $ 0.89 | $ 1.43 | $ 1.85 |
| Diluted EPS | $ 1.24 | $ 1.04 | $ 0.89 | $ 1.43 | $ 1.85 |
| Weighted Average Shares Outstanding | 2.65B | 2.67B | 2.67B | 2.61B | 2.56B |
| Weighted Average Shares Outstanding (Diluted) | 2.65B | 2.67B | 2.67B | 2.61B | 2.56B |
Currency in CNY
